Active Ingredient(s): Alectinib
FDA Approved: * December 11, 2015
Pharm Company: * HOFFMAN-LA ROCHE
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Alecensa Overview

Alectinib (INN,[2] marketed as Alecensa) is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK)[3][4] and is used to treat non-small-cell lung cancer (NSCLC). It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group. Contents 1 History, clinical trials, Approvals and medical uses 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacok...

Read more Alecensa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Alecensa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 150mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Alecensa: (1 result)

Sorted by National Drug Code
  • 50242-130 Alecensa 150 mg Oral Capsule by Genentech, Inc.

Other drugs which contain Alectinib or a similar ingredient: (1 result)